Genetic Risk for Alzheimer's Disease Moderates the Association Between Medial Temporal Lobe Volume and Episodic Memory Performance Among Older Adults.

Journal of Alzheimer's Disease : JAD
Sarah PrietoAlzheimer’s Disease Neuroimaging Initiative

Abstract

A complex set of interactions between biological, genetic, and environmental factors likely underlies the development of Alzheimer's disease (AD). Identifying which of these factors is most associated with AD is important for early diagnosis and treatment. We sought to examine genetic risk and structural brain volume on episodic memory in a sample of older adults ranging from cognitively normal to those diagnosed with AD. 686 adults (55-91 years old) completed a 3T MRI scan, baseline cognitive assessments, and biospecimen collection through the Alzheimer's Disease Neuroimaging Initiative. Hierarchical linear regression analyses examined main and interaction effects of medial temporal lobe (MTL) volume and polygenic hazard score (PHS), indicating genetic risk for AD, on a validated episodic memory composite score. Genetic risk moderated the relationship between MTL volume and memory, such that individuals with high PHS and lower hippocampal and entorhinal volume had lower memory composite scores [ΔF (1,677) = 4.057, p = 0.044, ΔR2 = 0.002]. Further analyses showed this effect was driven by the left hippocampus [ΔF(1,677) = 5.256, p = 0.022, ΔR2 = 0.003] and right entorhinal cortex [ΔF (1,677) = 6.078, p = 0.014, ΔR2 = 0.003]. Am...Continue Reading

References

Jan 1, 1991·Acta Neuropathologica·H Braak, E Braak
May 1, 1995·Neurobiology of Aging·H Braak, E Braak
Mar 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·W J StrittmatterA D Roses
Feb 8, 2006·Archives of General Psychiatry·Margaret GatzNancy L Pedersen
Sep 22, 2006·Lancet Neurology·Basil H RidhaNick C Fox
Dec 18, 2008·Expert Review of Neurotherapeutics·Carl A Gold, Andrew E Budson
Jan 20, 2010·Lancet Neurology·Clifford R JackJohn Q Trojanowski
Feb 10, 2011·The Journal of Neuropsychiatry and Clinical Neurosciences·Allison R KaupLisa T Eyler
Nov 15, 2011·Current Opinion in Neurobiology·Michela Gallagher, Ming Teng Koh
Jul 12, 2012·Brain Imaging and Behavior·Paul K CraneUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Aug 22, 2012·Cold Spring Harbor Perspectives in Medicine·Richard Mayeux, Yaakov Stern
Dec 15, 2012·Lancet Neurology·Karolien BettensChristine Van Broeckhoven
Mar 13, 2013·Lancet Neurology·Victor L VillemagneUNKNOWN Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group
Apr 5, 2013·PLoS Genetics·Frank Dudbridge
Nov 19, 2013·PloS One·Perry G RidgeUNKNOWN Alzheimer’s Disease Genetics Consortium
Nov 22, 2014·AJNR. American Journal of Neuroradiology·F D RaslauL P Mark
Feb 10, 2016·Biological Psychiatry : Cognitive Neuroscience and Neuroimaging·Theresa M Harrison, Susan Y Bookheimer
Aug 22, 2017·Current Neurology and Neuroscience Reports·Neha Raghavan, Giuseppe Tosto
Nov 15, 2017·Genome Medicine·Cathryn M Lewis, Evangelos Vassos
Apr 27, 2018·Psychiatry Investigation·Seok Woo MoonYoung Chil Choi
Dec 12, 2018·Molecular and Cellular Neurosciences·Michael SchöllWilliam Jagust
Mar 14, 2019·Frontiers in Aging Neuroscience·Xiwu WangUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Apr 30, 2019·Human Brain Mapping·Long XieUNKNOWN Alzheimer's Disease Neuroimaging Initiative

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.